Siglec-G represses DAMP-mediated effects on T cells

miR29a and miR378b Influence CpG-Stimulated Dendritic Cells and Regulate cGAS/STING Pathway

“…On other hand, CD273 and Siglec-G are immunosuppressive molecules. Siglec-G inhibits DC cross-presentation and suppresses the innate immune response [2,35,36]. CD273 binds to the programmed cell death protein-1 (PD-1) receptor on T-cells and causes downregulation of various functions, including T-cell proliferation and cytokine production [37].…”

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

“…Properly glycosylated CD52 has previously been identified as a ligand for Siglec-10 on human T cells (36). Furthermore, inhibitory mouse Siglec-G (often referred to as the murine paralog of human Siglec-10) was found to inhibit DAMP-associated T cell activation (37). These investigations demonstrate that Siglecs can dampen T cell responses in the context of general inflammation.…”

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

“…Binding of CD24 on tumors to Siglec‐10 on immune cells may therefore have prevented the suppression of TLR4 signaling of immune cells by inhibiting the binding of CD24 on immune cells to Siglec‐10. Moreover, increased production of CCL2 was observed only in tumors with low PD‐L1, which may be because Siglec‐10 is also expressed on B and T cells 42‐44 . It is possible that Siglec‐10 on tumor–infiltrating macrophages did not sufficiently bind to tumor CD24 because of the high lymphocyte infiltration in PD‐L1 high tumors.…”